SCHEMBL1639416

SCHEMBL1639416

Cc1cc(C(=O)N/N=C\c2c(O)ccc3ccccc23)[nH]n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.73
MEN1 O00255 9/20 0.62
KMT2A Q03164 9/20 0.62
NPC1 O15118 7/20 0.62
RAB9A P51151 7/20 0.62
POLB P06746 2/20 0.62
KLF5 Q13887 2/20 0.62
RRM1 P23921 3/20 0.60
PAX8 Q06710 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
KDM4E B2RXH2 2/20 0.59
MAPT P10636 2/20 0.59
HTT P42858 2/20 0.59
PSMD14 O00487 1/20 0.59
LMNA P02545 1/20 0.59
ALPI P09923 1/20 0.59
ALPG P10696 1/20 0.59
CASP3 P42574 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
DPP4 P27487 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639418 1.00 SPHK1 (0.73) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL12767408 1.00 SPHK1 (0.73) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL12767346 0.84 SPHK1 (0.69) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL30899246 0.84 SPHK1 (1.00) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL14501922 0.84 SPHK1 (1.00) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL8298508 0.84 SPHK1 (0.85) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL1639361 0.84 SPHK1 (0.69) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL19182914 0.84 SPHK1 (1.00) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL19182739 0.84 SPHK1 (1.00) SPHK1MEN1KMT2ANPC1RAB9A
SCHEMBL1639362 0.84 SPHK1 (0.69) SPHK1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
US-8507546-B2 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) 2013-08-13 US disclosed
US-8507546-B2 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) 2013-08-13 US disclosed
US-20120276121-A1 USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) 2012-11-01 US disclosed
US-20120276121-A1 USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) 2012-11-01 US disclosed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
US-20090324580-A1 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases CENIX BIOSCIENCE GMBH (DE) 2009-12-31 US disclosed
US-20090324580-A1 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases CENIX BIOSCIENCE GMBH (DE) 2009-12-31 US disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324580-A1 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases SCARB1, MSR1, HAVCR2 SPHK1 950/4885MEN1 4511/4885KMT2A 4757/4885
US-20120276121-A1 USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES SCARB1, MSR1, HAVCR2 SPHK1 950/4885MEN1 4511/4885KMT2A 4757/4885
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 SPHK1 2935/4885MEN1 2974/4885KMT2A 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.